Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.74 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.59 |
| ▸ | APLNR | P35414 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28690690 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| SCHEMBL29588982 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL59413 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| SCHEMBL29750348 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL25353366 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL172917 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL25418953 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL29350981 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| SCHEMBL29833896 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL28615809 | 0.99 | GNRHR (0.73) | GNRHRABCC2PTGS1C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080112888-A1 | IGFBP2 BIOMARKER | SCHERING CORPORATION | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080112888-A1 | IGFBP2 BIOMARKER | IGFBP2, IGFBP1, IGFBP5 | GNRHR 66/4885ABCC2 577/4885PTGS1 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.